Sydney-based building products group, Alesco has warned shareholders to expect a 31% fall in full year profit and a loss after asset impairment charges are taken into account.
In a statement to the ASX Thursday evening, Alesco (ALS) said full year EBITA before significant items is expected to be approximately $85 million, "representing a decrease of 31% from the previous year."
"Taking significant items into account, which include a $70 million impairment charge, Alesco is expecting to report a post tax loss of approximately $13 million," directors warned in the statement.
They said the figures were preliminary and subject to finalisation by auditors and the board before the release of the full year report on July 28. Alesco balances on May 31.
Alesco reported a 16% fall in operating profit for the six months to November and suspended dividend as it sought to renegotiate its debts with its banks.
Directors repeated the decision, revealed in May, that they had decided to resume paying a dividend, which would be set at the board meeting later this month.
"This result includes eleven month’s trading from the Scientific & Medical division which was sold on 30 April 2009. Earnings per share before amortisation and significant items are expected to be approximately 48 cents per share, a decline of 43% compared to the prior year."
"In response to the challenging external environment there has been a substantial rationalisation of the Company’s businesses during the year, resulting in approximately $21 million (after tax) in restructuring and other costs being charged in the year ended 31 May 2009.
"These costs include costs associated with the closure of the Robinhood manufacturing plant in Auckland, the reduced scale of the B&D manufacturing operations in Auckland, Marathon Tyres’ exit from the Hankook wholesale tyre business and redundancies associated with a reduction in the group’s overall workforce.
"The full year results will also include approximately $60 million profit after tax resulting from the sale of the Scientific & Medical division, including net foreign exchange effects.
"In addition, a post-tax charge of $10 million has been incurred associated with the closure of interest rate swaps resulting from the reduced debt levels following the sale of this division.
"The Company is currently reviewing the carrying value of its intangible assets (which consists mostly of goodwill) and, subject to finalisation, expects to incur an impairment charge of $70 million in the FY2009 financial results.
"This charge would relate in its entirety to the Water Products & Services division with no impairment charges in relation to the other cash generating units within the group.
"Alesco has a strong balance sheet following the sale of the Scientific & Medical division at 30 April 2009 and the cancellation of the interim dividend.
"As at 31 May 2009 the group had net debt of approximately $160 million (down from $333.9 million at the half-year) equating to gearing (on a net debt to net debt plus book equity basis) of 23%.
Alesco has sound and cash generative businesses and the Board is confident that Alesco is well positioned in the current challenging environment.
"As previously announced to the market, it is the Board’s intention to resume paying dividends. The quantum of the dividend will be determined at the July Board meeting when the full-year results are finalised," the company said.
